Purpose: SIR-Spheres are radioactive yttrium 90 microspheres (SIR-Spheres®, Sirtex Medical Limited, Australia) used to selectively target high levels of ionising radiation to tumors within the liver. This trial was designed to measure any increased patient benefit by adding a single administration of SIR-Spheres to a regimen of regional hepatic artery chemotherapy (HAC) administered as a 12 day infusion of floxuridine and repeated at monthly intervals, vs. the same chemotherapy alone.
Introduction
Cancer of the gastro-intestinal tract commonly metastasises to the liver as a result of the portal venous drainage of the gut [1] . For many patients with disseminated large bowel cancer, the liver represents either the dominant or only site of metastases, and is a major cause of patient mortality [2] . For a minority of patients with a limited number of liver metastases, some form of locally ablative treatment such as surgical removal, cryotherapy or radiofrequency ablation can offer the chance of long term survival. However, for most patients with metastatic liver cancer, the disease is well beyond any form of locally ablative treatment by the time it is diagnosed.
The mainstay of treatment for advanced liver metastases is either systemic or regional chemotherapy. Systemic chemotherapy using 5-fluorouracil and leucovorin has been extensively evaluated for patients with advanced colorectal cancer and shown to result in tumor response rates of the order of 10%-20% and a small survival benefit [3, 4] . More recent trial evidence has shown that the response rate and survival for this group of patients can be further enhanced by the addition of newer agents including irinotecan [5, 6] and oxaliplatin [V] .
Regional treatment of the liver by hepatic artery chemotherapy (HAC), usually with 5-fluorouracil or floxuridine, has been used for many decades for treating advanced liver metastases. Although many trials have reported higher response rates for HAC, there remains doubt over whether this form of regional chemotherapy confers any major additional survival advantage when compared to systemic chemotherapy [8] . There is clearly a need for more effective treatments for this large patient group.
Selective Internal Radiation Therapy (SIRT) has been developed for the treatment of advanced non-resectable primary and metastatic liver cancer. The technique in-volves embolising radioactive yttrium 90 SIR-Spheres® into the arterial blood supply of the liver. Because both primary and metastatic tumors within the liver are supplied almost entirely by blood from the hepatic artery, as opposed to the normal liver parenchyma, the SIR-Spheres® concentrate selectively in the tumor compartment within the liver [9] . This physiological tumor targeting can be enhanced by injecting Angiotensin-2 into the hepatic artery immediately before the administration of the SIR-Spheres®. For a period of several minutes the Angiotensin-2 causes the normal liver arterial blood vessels of the liver to constrict, but not those supplying the tumor [10] . If the SIR-Spheres® are injected during this time, they will further concentrate within the tumor microvasculature.
SIR-Spheres® (Sirtex Medical Ltd, Australia) are radioactive yttrium 90 microspheres that were developed with optimal characteristics for administration of Selective Internal Radiation Therapy (SIRT) to patients with advanced non-resectable liver cancer. Earlier reports from both our research group and others have shown that treatment with SIR-Spheres® results in a high response rate for patients with metastatic liver cancer [II, 12, 13] . Other similar studies have shown that SIRSpheres® are also effective in causing regression and increasing survival for patients with primary hepatocellular cancer [14] .
These high response rates were the basis for conducting a randomised controlled trial to assess whether a single injection of SIR-Spheres® could increase the tumor response rate, time to disease progression in the liver, survival, and to measure treatment related toxicity or change in quality of life.
20% to 55% with 80% power and 95% confidence and an increase in median time to disease progression for control group patients of 4.5 months by 32% with 80% power and 95% confidence. Based on a sample size of 74 patients, the power to detect an absolute 30%) increase in survival at six months from 50% to 80% is 70% with a 95% confidence level.
Therefore, the Trial Co-ordinators considered it acceptable to reduce the chance of showing a survival improvement in view of the fact that response and time to disease progression had become primary outcome measures in the study.
Patients were stratified before randomisation into three groups depending on the percentage of liver involved with tumor (viz; < 25%, 25%-50%, > 50). All patients were fully informed of the nature of the trial and signed informed consent to enter the study. 
Patients
All patients had undergone complete surgical resection of a primary adenocarcinoma of the large bowel. Only patients with non-resectable metastases limited to the liver and lymph nodes in the porta hepatis were included in the study. The porta hepatis lymph nodes are the draining lymph nodes of the liver and are difficult to assess on CAT scan but are occasionally found to be involved with tumor at the time of surgery. Patients were required to have WHO performance status 0-2, have adequate haematological and hepatic function and not have clinical evidence of cirrhosis or ascites. Patients who had already received systemic chemotherapy for treatment of their metastases were eligible for trial entry, but were excluded if they had received radiotherapy to the liver. All patients had bi-lobar liver metastases and were reviewed in a surgical oncology unit to confirm that the metastases were so advanced that they were unable to be treated by any form of local ablation. Patients in whom the liver metastases could be treated by any form of local ablation such as surgical resection or cryotherapy were excluded from the study.
Patients and methods

Trial design
Patients with non-resectable liver metastases from primary adenocarcinoma of the large bowel, but without distant metastases. were randomised using a blinded envelope batch method controlled by an independent person Treatment consisted of either a regimen of hepatic artery chemotherapy (HAC) with floxundine (FUDR. Control Arm) or the same chemotherapy plus a single injection of SIR-Spheres (Investigational Arm). The trial was originally designed to enter 95 patients, but was closed for accrual in 1997 after entering 74 patients. The decision to cease accrual was made due to i) increasing reluctance of both patients and their referring medical practitioners to have patients randomised which resulted in a diminishing accrual rate, ii) absence of ongoing funding for the trial and in) a statement in 1996 by the Food and Drug Administration (FDA) that treatment related response and time to disease progression were acceptable criteria to support a Pre Market Application to the FDA for registration of SIRSpheres* in the USA.
The Principal Investigators considered that if the trial were to show a significant improvement in response and/or time to disease progression, then this would be a clinically important outcome, even though the study would be underpowered to show the original required increase in median survival of the investigational arm of 30% over the control arm with 90% power and 95% confidence. The decision to cease accrual at 74 patients was supported by the fact that this number of patients would still allow detection of an increase in response from Investigations Before trial entry, all patients underwent a battery of serologic tests to determine haematological, renal and liver function and a serum CEA. Imaging studies were undertaken to determine the extent of disease in the liver and to look for evidence of extra-hepatic malignancy Compulsory imaging tests included contrast enhanced CAT scans of the whole abdomen and pelvis. CAT scans of the lung and a nuclear medicine bone scan. Patients underwent a trans-femoral hepatic arteriogram to aid the surgical placement of the access catheter.
All patients underwent a full laparotomy by the same surgical oncologist in order to confirm the non-resectable status of the metastases, look for evidence of intra-abdominal spread of the tumor and to insert an hepatic artery catheter and port through which all treatment would be administered. Patients were randomised after insertion of the hepatic artery catheter and port.
Patients randomised to receive SIR-Spheres* underwent a nuclear medicine scan to determine the amount of SIR-Spheres® that would pass through the liver and lodge in the lungs. This was performed by injecting technetium-99 labelled macro-aggregated albumin (MAA) into the port and measuring the radioactivity in the liver and lungs using a gamma camera. Areas of interest were drawn around the liver and lungs and the percentage of the MAA that lodged in the lungs was determined as a fraction of the total amount of MAA in both lungs and liver. This was recorded as a 'lung break-through percentage' in order to decide whether to reduce the amount of activity to administer to the patient. Previous experiments had shown that a lung breakthrough percentage of >10%> might result in radiation pneumonitis and should be accompanied by a reduction in the amount of yttrium-90 activity administered to the patient [15] . This technique has been shown to be a reliable method for determining the subsequent distribution of SIR-Spheres®.
The tumor and liver volumes were calculated from the serial slices of the pre-treatment CAT scan and recorded as a tumor/total liver volume ratio as described previously [16] .
Data handling and recording of response
All source data for this trial has been independently monitored and audited before being subjected to analysis and interpretation.
As response to treatment was a primary end point of this trial, several methods have been used to record these events Conventional methodology is to record serial changes in both tumor size and changes in serum tumor markers. The most common method of recording tumor size is to record changes in the sum of the products of cross-sectional diameters of all measurable lesions seen on serial CAT scans from which the total tumor area is calculated and which is then used to determine response. Several reports have indicated that using tumor areas calculated from cross-sectional diameters to determine response to treatment is not optimal in assessing response of liver tumors and have advocated the use of serial changes in tumor volume as a more accurate measure of response [16] . Our experience supports this assertion and therefore, tumor volumes as well as tumor areas have been independently recorded in this trial.
In order to decrease observer error when recording tumor volume response, two medical practitioners not associated with the trial independently and blindly evaluated all serial CAT scans on all patients. The outline of all tumors on the serial CAT scans were manually traced and the tracings were then digitised by a third independent operator using a graphics tablet. Data was transferred to a computerised data-handling package that calculated the total tumor and liver volumes by multiplying the tracing areas by the thickness of the CAT scan slice. By adding the volumes for each CAT scan slice, the total tumor volume and liver volume can be calculated. As part of the independent validation mechanism, if one observer's record of a tumor volume varied by more than 10% from the mean of the two observers' measurements, then the scans were independently traced by a third observer. The 'average tumor volume' was then taken as the mean of the two closest values. In addition, changes in tumor area were independently evaluated by a third observer. This produced a further data set to evaluate response to treatment.
Serial changes in CEA have repeatedly been shown to be a reliable correlate of survival for patients with disseminated colorectal cancer undergoing treatment [17, 18] . Therefore, tumor response was also calculated from changes in serum CEA levels. As the assay for CEA changed during the conduct of the trial, appropriate reference ranges were used to calculate response using CEA levels Tumor response using CEA was only used for patients in whom the serum CEA was elevated before start of protocol treatment.
Response and quality of life
As this trial was conducted in two Australian teaching hospitals, cost constraints demanded that the trial protocol be structured so that follow-up CAT scans were performed only at three-monthly intervals, rather than four-weekly intervals. This substantially increased the severity of the definitions for response for each of the three criteria which were;
A partial response (PR) was defined as an objectively measured decrease in tumor size, measured for both areas and volumes, by 50% or more on two successive CAT scans not less than three months apart and after randomisation and before evidence of Progressive Disease in the liver and before any non-protocol treatment had been given.
A complete response (CR) was defined as the disappearance of all tumor on two successive CAT scans not less than three months apart and after randomisation and before evidence of Progressive Disease in the liver and before any non-protocol treatment had been given A CEA complete response (CEA CR) was defined as a decrease in serum CEA into the normal range on any occasion after randomisation but before evidence of Progressive Disease and before any nonprotocol treatment had been given. A CEA partial response (CEA PR) was defined as a decrease in serum CEA by 50% or more, but not into the normal range, on any occasion after randomisation and before evidence of Progressive Disease and before any non-protocol treatment had been given.
Progressive disease in the liver (PD) used the same three objective measures that determine Response to treatment and was defined as i) an increase on any occasion in cross-sectional tumor area, or tumor volume, by 25% or more over the nadir as measured on serial CAT scans, or ii) the development of new lesions in the liver or iii) an increase on any occasion in the serum CEA by 25% or more over the nadir for those patients with an elevated CEA at the time of randomisation For patients in whom there was an increase in CEA. this was attributed to Progressive Disease in the liver, provided that there was no evidence of new lesions at any site other than the liver.
No change (NC) was defined as either a decrease in tumor area, volume or CEA that is less than that required for a Partial Response, or an increase that is less than that required for Progressive Disease.
Not assessable (NA) for any of the response criteria was attributed to those patients who had either i) no follow-up CAT scans due to rapid deterioration after randomisation, ii) had unmeasurable index lesions for estimating cross-sectional tumor areas, or iii) for the purpose of measuring response by CEA. did not have an elevated CEA at the time of randomisation.
Quality of life was recorded at three-monthly intervals using a validated 13 point linear analogue Self Assessment Scale recommended by Pnestman and Baum [19] .
Statistical analysis
A variety of statistical techniques have been used to analyse the outcome data from this study Outcome criteria were analysed on an intention-to-treat basis. The conditional binomial exact test (Rice 1988) was used to compare the outcomes that are expressed as proportions in each of the two treatment arms. The logrank test was used to compare time to event data in the presence of censored observations. Modelling of hazard ratios was performed using the method of Cox and 'time-dependent' adaptation of Cox modelling was performed along the lines described by Harrell and Lee. Times to event curves were constructed using the method of Kaplan-Meier. Times to event curves from time-dependent analyses were derived from the appropriate Cox models as a postiche exploratory analysis. An exploratory Cox regression analysis was performed for patients surviving either less than, or more than. 15 months. This time period was chosen as there was a clear divergence in the survival curves between patients treated with the control or investigational treatment arm at this time and further scrutiny of the data demonstrated that the pattern of cause of death was different for patients dying either before, or after, 15 months. Responses achieved were compared using the Kruskal-Wallis test. Mean Quahty-of-Life scores were compared for each time interval between treatment groups using independent t-tests As experience prior to this trial had shown that the addition of SIRT to HAC was safe and resulted in high response rates, the trial protocol was originally designed and written to measure only any increase in efficacy criteria resulting from the addition of SIRSpheres"". However, in this report all /"-values have been derived from two-tailed tests of significance. No interim analyses were performed on any of the data
Treatment
Surgery
Patients in both treatment arms underwent a laparotomy. cholecystectomy and insertion of a permanent hepatic artery catheter that was connected to a subcutaneous access port by the same surgical oncologist. At laparotomy a search was made for extra-hepatic metastases and patients were excluded from the trial if there were metastases outside the liver and portal lymph nodes that could not be completely excised. The hepatic artery catheter had an internal diameter of 0.8 mm as smaller bore catheters had been shown to occasionally block during the administration of SIR-Spheres*. Accessory hepatic arteries were ligated in order to ensure that the catheter perfused the whole liver. Perfusion of the whole liver by the catheter was checked during the surgical operation by injecting fluorescein through the catheter and observing the liver under ultra-violet light. The catheter was re-positioned if needed in order to ensure perfusion of the whole liver. Care was taken to ligate the small vessels passing back from the hepatic artery to the duodenum and stomach to prevent SIR-Spheres® from flowing to those organs. The omentum was tacked in between the stomach and liver to shield the stomach from any radiation emanating from the liver
Selective internal radiation therapy (SIRT)
The first patient that received the combination of SIRT plus HAC had the SIR-Spheres* administered at the time of the laparotomy to insert the access port. Although there was no treatment-associated toxicity in this patient, in order to improve the logistics of administering SIRT, all subsequent patients had SIR-Spheres® administered after recovery from surgery and within four weeks of the surgical procedure to insert the hepatic artery access port. SIR-Spheres® were administered by inserting a needle into the subcutaneous access port and this was connected to a customised SIR-Spheres® delivery set. Fifty micrograms of Angiotensin-2 (Ciba) were injected into the hepatic artery over a period of thirty seconds. Thirty seconds later the SIR-Spheres® was injected into the hepatic artery through the access port. This injection of SIR-Spheres* was pulsed into the hepatic artery over a period of several minutes to obtain good mixing in the hepatic arterial blood stream.
Patients randomised to receive SIRT were treated with a predetermined quantity of SIR-Spheres that was varied depending on the size of the tumor. Patients with tumor that was either <25%, 25%-50% or > 50% of the total liver volume were given SIR-Spheres® equivalent to either 2GBq. 2.5GBq or 3GBq of yttrium 90 activity. Provision was made for patients in whom the lung-liver break through scan indicated that more than 10% of the microspheres passed though the liver and lodged in the lungs. This required a reduction in the amount of yttrium 90 activity to be administered by 2%> for each 1% that the lungliver break-through percentage was greater than 10%. Although there was the provision for reducing the dose of SIR-Spheres® if the lung breakthrough ratio was greater then 10%, no patient required this reduction. Patients were usually discharged home either the same day or the following day after SIRT.
Protocol chemotherapy
Protocol Chemotherapy is defined as the administration of FUDR at any dosage and administered into the hepatic artery port but before any other chemotherapy (i.e., non-protocol chemotherapy) was administered. If any non-protocol chemotherapy was administered to any patient after randomisation, either via the hepatic artery port or systemically. then the last date of Protocol Chemotherapy was deemed to be the date of the last administration of FUDR alone through the hepatic artery port.
All patients in both treatment arms received 12 day cycles of continuous infusion floxuridine at 0.3 mg/kg of body weight/day that were repeated at four weekly intervals. Protocol Chemotherapy was continued for 18 cycles or until there was evidence of either tumor progression within the liver, the development of extra-hepatic metastases necessitating a change to systemic chemotherapy, unacceptable toxicity. port failure or at the patient's request. The authors have experience with this protocol of HAC and consider it well tolerated.
Non-protocol treatment
Once protocol treatment ceased, further cancer specific treatment, including non-protocol chemotherapy, was allowed to best manage patient care. All non-protocol cancer specific treatment was recorded in all patients. Other supportive, but not cancer specific treatment was allowed for patient management.
Toxicity
Toxicity was recorded using standard UICC criteria
Follow-up
All patients were followed at monthly intervals while on protocol treatment and not less than three-monthly thereafter. Follow-up was with physical examination and serologic tests including monthly full haematological screen, liver function tests and CEA and threemonthly CT scans of the abdomen.
Quality of life
Quality of life was measured before the start of treatment and at three-monthly intervals thereafter using a validated II-question linear analogue self-assessment questionnaire.
Results
Patient and tumor characteristics
The trial remained open for patient entry from 1991-1997 and entered 74 patients, of which 70 were eligible for trial entry and were treated and followed according to trial protocol requirements. Four patients were deemed 'ineligible' for trial treatment, follow-up and analysis due to the presence of unconfirmed disseminated cancer at the time of randomisation that was subsequently confirmed. These patients were flagged and outcome analyses performed both with and without inclusion of these four patients. There are no significant differences in any of the outcome results if the data is analysed with or without the inclusion of these four patients. Therefore, the results presented here are for eligible patients only. At the time of this analysis four patients remain alive (three in the SIRT + HAC arm and one in HAC alone arm) and all patients have been followed up for a minimum period of 3.5 years after randomisation.
Analysis of patient and tumor characteristics demonstrates that there is no significant difference in any of these characteristics between the two treatment groups (Table 1) . This confirms the effectiveness of the trial randomisation process.
Selective internal radiation therapy
Thirty-five of the 36 patients randomised into the Investigational Arm actually received treatment with SIRT + HAC. One patient with advanced metastases deteriorated rapidly after trial entry and died before any protocol treatment could be started. All 34 patients in the control arm received HAC.
The thirty-five eligible patients that were treated with SIRT received a mean of 2.156 ± 0.324 (SD) GBq of yttrium 90 activity. Five patients received less and one patient more than the designated protocol amount of 90 yttrium 90 activity, but all six of these patients received within 90% of the 2-3 GBq of yttrium 90 activity required by the protocol. The three ineligible patients in this treatment arm received a mean of 2.276 ± 0.231 GBq of yttrium 90 activity. Some patients experienced discomfort in the upper abdomen after the implantation of SIR-Spheres but this subsided rapidly either spontaneously or with analgesia. One patient developed mild pancreatitis after SIRT + HAC that settled within three days but caused exacerbation of pre-existing diabetes. There were no other major complications resulting from treatment with SIR-Spheres.
Protocol Chemotherapy
There was no difference in the amount of Protocol Chemotherapy administered to patients in either the Investigational or Control Arms of the trial when measured by amount of chemotherapy (mean 1863 ± 1735 mg FUDR vs. 1822 ± 1323 mg FUDR per patient), or number of cycles of chemotherapy (mean 8.7 ± 5.6 vs. 8.0 ± 5.0 cycles per patient).
Non-protocol treatment
Many patients received non-protocol chemotherapy during the course of their illness after cessation of Protocol Chemotherapy. The main drugs used were systemic chemotherapy with 5-fiurouracil plus Leucovorin and Mitomycin-C given either systemically or into the hepatic artery port or FUDR given off-protocol into the hepatic artery port. If any non-protocol chemotherapy was added in any patient while the hepatic artery FUDR was continued, then the FUDR was considered to be non-protocol chemotherapy from that date. The total amount of the each of the three most commonly used non-protocol chemotherapy drugs was higher for the patients in the Control Arm. In the case of 5-fluorouracil, patients on the Control Arm received approximately 36% more, and for FUDR, 59% more in the period following cessation of protocol treatment. The fact that patients in the Control Arm received more non-protocol chemotherapy than patients in the Investigational Arm indicates that the improved outcome benefits observed for patients receiving the combination treatment cannot be attributed to greater quantities of non-protocol chemotherapy.
Response
Response measured by the three criteria are shown in the following Tables 2a, 2b and 2c. One patient in each arm had their disease reduced to such an extent that they were subsequently deemed surgically resectable and underwent surgical excision of the metastases. The patient treated with SIRT + HAC has since remained disease free for eight years and the patient treated with HAC alone subsequently developed recurrent cancer in the liver and lungs.
When response is assessed by changes in cross-sectional tumor areas, more than twice as many patients receiving SIRT achieve either a Complete or Partial Response and this difference is highly significant (18% vs. 44% P = 0.01). When measured by changes in tumor volume a similar difference is evident (24% vs. 50% P -0.03). Responses measured by changes in CEA strongly support the findings of changes in tumor areas and volumes and confirm that significantly more patients treated with SIRT + HAC will respond compared with HAC alone (47% vs. 72% P = 0.004). By all measures of response (volumes, areas and CEA) more patients in the HAC alone arm had Progressive Disease as their best response to treatment.
Time to progressive disease in the liver
Progressive disease (PD) in the liver is an objective measure of cancer progression that indicates the current treatment is no longer effective. As both treatment regimens in this trial are delivered directly into the hepatic arterial circulation, they only have potential to affect tumor within the liver and have virtually no affect on cancer at other sites. Time to progressive disease in the liver is measured as the time from randomisation to the time at which PD was recorded. For patients in whom there was no objective measure of PD as defined above, then PD is defined as the date of death. For patients in whom there was no objective evidence of PD and who are still alive, then the date of last follow-up has been used. Figures 1 and 2 provide time to progressive disease in the liver using cross-sectional tumor areas and tumor volumes as measures of disease progression.
Survival
Survival is defined as the time from randomisation to death or last follow up if still alive. Table 3 and Figures 3  and 4 present comparisons of survival between the two treatment groups.
The Kaplan-Meier analysis shows a non-significant trend towards increased survival for patients treated with SIRT + HAC, compared with those receiving HAC alone. The hazard ratios suggest that patients receiving HAC alone have approximately a 40% higher death rate than for patients receiving SIRT + HAC. A test for proportional hazards did not show any evidence of departure from the proportionality assumption. An exploratory Cox regression analysis suggests that patients treated with the combination of SIRT + HAC who survive more than 15 months experience a survival advantage compared with those treated with HAC alone. This survival advantage is not evident for patients surviving less than 15 months. The period of 15 months was chosen for this analysis as there was a divergence of survival curves at this time and subsequent investigation showed that there was a markedly different pattern for the cause of death for patients surviving either less than, or more than, 15 months.
Cause of death
Sixty-five of the seventy patients have died and four remain alive (three patients in the investigational arm and one patient in the control arm). One patient treated with SIR-Spheres is considered permanently cured and has been disease free for more than eight years, while the other three patients all have existing disease that will eventually prove fatal.
At the time of randomisation all patients had metastatic cancer that was limited to the liver and draining portal lymph nodes. Many patients subsequently developed extra-hepatic dissemination of their cancer, which either was, or contributed to, the cause of death. Therefore, all patients that died were considered to have died from i) progression of the liver metastases if there was no evidence of extra-hepatic metastases at the time of death or ii) dying from disseminated cancer if extrahepatic metastases had developed at the time of death.
As both SIRT and HAC are both regional treatments only, the ability to control progression of the liver metastases could only translate into a survival benefit for those patients that did not rapidly develop and die of disseminated extra-hepatic disease. Therefore, the cause of death has been analysed for patients dying before and after 15 months from randomisation.
Twice as many patients that received HAC alone died of progression of the liver metastases as the sole cause of death (53% vs. 27%). The risk of death from progression of the liver metastases was 3.1 times higher (95% confidence interval (95% CI): 1.1-8.8, P -0.03) for patients receiving HAC only compared to those treated with the combination of SIRT + HAC. The reasonable interpretation of this finding is that patients that do not rapidly develop extra-hepatic disease are more likely to benefit from the greater control of the liver metastases resulting from treatment with the combination of SIRT + HAC.
Toxicity
The main toxicity events that occurred were changes in liver function tests. There were more grade 1 and 2 toxicity events in patients receiving SIRT + HAC for assessments of liver function tests (300 vs. 207 events) and nausea and diarrhoea (16 vs. 11 events). However, there was no difference in the rate of any grade 3 and 4 toxicity events between the two treatment arms (23 events in each arm). The profile of grade 3-4 toxicity events is detailed in Table 4 . Grades 1 and 2 changes in liver function tests are of minor importance in the clinical setting of patients with liver metastases and are frequently abnormal as a result of the liver tumor itself. It can be concluded that the addition of SIRT to HAC does not significantly increase any major toxicity that is clinically relevant.
Quality of life (QOL)
Of the 11 measures used in this assessment, only sexual interest/ability deteriorated over the 18 month period during which protocol treatment was administered. For all of the other measures used, the trend was towards improvement in the QOL scores over the first 18 months for both treatment groups. After this period there was often some deterioration in QOL scores, but this was usually related to recurrence of disease and/or associated with other treatment. Both treatment regimens tended to improve and not deteriorate quality of life. There was no significant difference between the treatment groups for any of the measures indicating that there is no major adverse impact on QOL of life resulting from the addition of SIRT to HAC.
Discussion
Systemic chemotherapy is widely used to treat patients with disseminated colorectal cancer, including those with liver metastases. The combination of 5-fluororacil and leucovorin has been the most common chemotherapy regimen in this setting during the past decade. Although a small percentage of patients will respond to treatment with this chemotherapy regimen, the survival advantage is minimal [20] . More recently other systemic agents have shown promise when used either alone or in combination with 5FU/LV. In a recent randomised trial involving 683 patients with metastatic colorectal cancer, the combination of 5FU/LV combined with irinotecan was shown to result in a greater response, increased progression free survival and increase in survival when compared to 5FU/LV alone [5] . Other new drug combinations such as oxaliplatin have also shown promise for treatment of this patient group [7] Continuous hepatic artery chemotherapy (HAC) using either floxuridine of 5-FU has been used for several decades for treatment of liver metastases and has been shown to result in a higher response rate than for systemic chemotherapy [21] . Biliary sclerosis has been reported as a problem with continuous high dose floxuridine given as a hepatic artery infusion, but may be overcome by using 5-fiuorouracil rather than floxuridine as the infused drug, and this may be achieved while maintaining the high response rate [22] .
Two recently published meta-analyses compared patient outcomes for HAC and systemic chemotherapy. These analyses showed HAC resulted in a higher response rate than systemic chemotherapy and suggested a small survival advantage as well. There is doubt however whether this minor improvement can be justified as the administration of HAC requires the surgical implantation of an access port [8, 23] .
External beam radiotherapy is rarely used to treat liver cancer, as the radiation doses that can be used are limited by the tolerance of the normal liver tissue. The technique of embolising radioactive microspheres into the arterial circulation of the liver was first reported several decades ago, but was abandoned because of poor targeting characteristics of the particles and leaching of the radionuclide from the microsphere matrix. Solid glass microspheres were then developed in an attempt to overcome the problem of leaching. However, the reports on the use of glass microspheres conclude that they are associated with a low response rate in both primary and metastatic liver cancer. In the combined experience of six published studies using solid glass microspheres and involving 66 patients, an objective response of less than 10% was obtained [24] [25] [26] [27] [28] . Solid glass microspheres have also been reported as depositing in other organs outside the liver such as the duodenum and stomach, thereby causing significant radiation damage to those organs. In one report there was also a poor correlation between the radiation dose delivered to the liver by glass microspheres and the nuclear scans that are used to determine radiation dose to various organs [14] .
SIR-Spheres® were developed with physical characteristics to optimise targeting of tumors and ensure that leaching of the radionuclide does not occur. The research group at the Cancer Research Institute Inc. has extensively investigated the parameters necessary for targeting microspheres in order to deliver high radiation doses to liver tumors. Investigations have included the physiological mechanisms of tumor targeting [32, 34] , microsphere characteristics [30] , tissue tolerance to microsphere irradiation [36] , radiation dosimetry [34, 35] and enhanced tumor targeting with vasoactive drugs [10, [36] [37] [38] . This has allowed resurgence of interest in the use of SIRT for the treatment of advanced liver cancer. SIR-Spheres® have now been used in several clinical trials for treating patients with both primary and metastatic liver cancer.
We have previously reported our experience in treating patients with liver metastases from large bowel adenocarcinoma with either SIR-Spheres® alone or in combination with hepatic artery chemotherapy. In 16 patients treated with SIR-Spheres® alone the CEA fell in all patients and the majority experienced a reduction in tumor volume [11] . In a further phase II trial involving 71 patients with advanced colorectal liver metastases, SIR-Spheres® were combined with hepatic artery chemotherapy with higher tumor regression rates that have been reported using chemotherapy alone with more than 85% of patients demonstrating at least some level of tumor regression on serial CAT scans at three months after treatment [12] . Others have also reported high response rates for this group of patients treated with SIR-Spheres® in combination with chemotherapy [13] . Similarly, high response rates have also been reported using SIR-Spheres® to treat patients with advanced primary liver cancer [14] .
As a result of this experience, this randomised trial was undertaken to assess any increase in outcome criteria that measure treatment effect for patients with advanced liver metastases, over and above that achieved by HAC. HAC was chosen as the control arm in this trial as it has been shown until now to have the highest response rates and to improve survival in this patient group.
The results of this randomised study conclude that the addition of a single injection of SIR-Spheres® to hepatic artery chemotherapy more than doubles the tumor response rate and significantly increases the time to disease progression. Survival appears to be improved to a lessor extent for those patients that do not die from extra-hepatic metastases within 15 months of starting treatment. This enhanced survival for patients who are treated with SIRT and do not rapidly develop extrahepatic disease mirrors the experience of Stubbs et al. [39] .
The response rates and survival for patients treated with SIR-Spheres® reported here are consistent with the results from other studies using the SIRT technique. As with other reports using SIR-Spheres®, we did not observe any increase in severe treatment-related toxicity and conclude that treatment with SIRT in experienced hands is generally a safe procedure.
The response rate for patients treated with HAC alone appears low in comparison with previously reported studies. However, as previously detailed, followup CT scans were only performed at three monthly intervals due to cost constraints in the Australian Public Health system. Therefore, in order to qualify as a partial or complete response, a response has to be observed firstly at not less than three months after starting treatment with a confirmatory response at not less than three months later. Furthermore, the survival rate for patients treated with HAC alone in this trial is almost identical to that reported in the meta-analysis for similar patients treated with HAC [8] .
As patients with liver metastases usually have few or no symptoms and a comparatively good quality of life, the addition of SIR-Spheres® might be expected to compromise quality of life. No decrease in quality of life was observed which is in accord with the lack of serious toxicity and treatment-related complications.
In summary, this randomised trial has demonstrated that adding a single injection of SIR-Spheres® to a standard regimen of hepatic artery chemotherapy significantly increases treatment effectiveness when measured by tumor response and time to disease progression and suggests an increase in survival for patients surviving more than 15 months. Treatment with SIR-Spheres® does not compromise quality of life or add significant toxicity.
As newer drugs such as irinotecan, oxaliplatin and capecitabine have recently become available for treating metastatic colorectal cancer, further trials are underway to evaluate the effect of combining these drug combinations with SIR-Spheres®.
